21 November 2024 in Clinical Infectious Diseases
Shigella sonnei has caused sexually transmitted enteric infections in men who have sex with men (MSM) in Vancouver. We recently observed a high rate of multidrug-resistant (MDR) S. sonnei bacteremia among persons experiencing homelessness (PEH). We aim to describe the wider epidemiology, clinical outcomes, and genomics of S. sonnei infections over time. A retrospective review of 163 patients with S. sonnei infections was undertaken from 2015 –2022. We collected demographic, clinical, and microbiological data over two time periods: historical (2015-2020) and recent (2021-2022). Severe shigellosis definition included hospitalization, bacteremia, or death. Whole genome sequencing was performed to identify genotype, infer relatedness, and predict antimicrobial resistance. S. sonnei infections rose from 8.3 (historical-period) to 56.5 cases/year (recent-period). Over time, the primary population characteristics associated with shigellosis shifted from MSM (45, 98%) to PEH (86,77%). The population intersection between MSM and PEH historically and recently was similar and occurred in three (6%) and ten (9%) of patients, respectively. Severe shigellosis was significantly higher in the recent compared to historical period (69 [61%] versus 7 [14%], p<0.001). A dominant clone of MDR S. sonnei, 3.6.1.1.2 (CipR.MSM5), emerged with resistance to all first and second-line agents yet with susceptibility to ceftriaxone. We observed a substantial increase in severe shigellosis and shift from sexually transmitted S. sonnei infections in MSM to likely environmental transmission among PEH. More severe disease associated with the 3.6.1.1.2 clone of MDR S. sonnei in PEH could be a result of underlying vulnerabilities of the affected population. This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/increased-severity-of-multidrug-resistant-shigella-sonnei-infections-in-people-experiencing-homelessness
9 April 2025 in Journal of Antimicrobial Chemotherapy
Introduction: Helicobacter pylori is associated with gastrointestinal diseases including gastritis and peptic ulcers. Despite its significance, there is a scarcity of antimicrobial susceptibility testing (AST) data available for this organism in North America. Objectives: The aim of this study was to assess the AST profile and identify factors associated with H. pylori culture positivity in a cohort of patients with refractory H. pylori undergoing gastric biopsies. Methods: We retrospectively reviewed gastric biopsy specimens received for culture between July 2009 and February 2023. We analyzed specimen transport time, Gram smear results, direct urease test findings, culture positivity and AST profiles. Using gradient strip methodology and European Committee on Antimicrobial Susceptibility Testing breakpoints, AST was conducted for amoxicillin, clarithromycin, metronidazole, levofloxacin and tetracycline. Results: Of 579 biopsy samples received for H. pylori culture, 228 (39.4%) tested positive. Samples transported within <1 h had significantly higher odds (1.81 times, P < 0.015) of being culture positive compared to those with longer transport times. Smear-positive samples had substantially higher odds (18.8 times, P < 0.001) of culture positivity compared to smear-negative. Urease-positive samples demonstrated notably higher odds (7.7 times, P < 0.001) of culture positivity compared to urease-negative samples. The collection of isolates from gastric biopsies showed susceptibility rates of 97.3% to amoxicillin, 99.1% to tetracycline, 50.4% to levofloxacin, 25.9% to metronidazole and 12.9% to clarithromycin. Conclusions: Short sample transport time was associated with improved H. pylori recovery rates. In this cohort of refractory H. pylori cases, susceptibility rates were high for amoxicillin and tetracycline and low for clarithromycin, metronidazole and levofloxacin. Susceptibility rates remained stable over time.
13 January 2025 in Journal of Clinical Virology
Background: Next-generation sequencing (NGS) for Hepatitis B virus (HBV) antiviral resistance (AVR) testing is a highly sensitive diagnostic method, able to detect low-level mutant subpopulations. Our clinical virology laboratory previously transitioned from DNA hybridization (INNO-LiPA) to NGS, initially with the GS Junior System and subsequently the MiSeq. The Oxford Nanopore Technology (ONT) sequencing system was evaluated for HBV resistance testing, with regards to sequencing accuracy and turn-around time. Methods: We performed amplicon sequencing of the HBV polymerase gene from patient plasma and external quality assessment (EQA) samples on the MiSeq Reagent Nano Kit v2 and GridION ONT with R10.4.1 flowcells. Mutational analysis and genotyping were performed by DeepChek (R) Assay-HBV (version 2.0). Results: A total of 49 patient samples and 15 EQA samples were tested on both the MiSeq and ONT. There was high agreement for both patient and EQA samples between the MiSeq and ONT systems, with regards to total drug resistance mutations detected and total patient sample agreement, 68/70 (97 %) and 47/49 (96 %), respectively. Conclusion: The ONT NGS platform provided accurate HBV AVR results, with improved turn-around times. Sequencing error rates at AVR codons were below 1 %.
5 December 2025 in Diagnostic Microbiology and Infectious Disease
Metallo-β-lactamase (MBL)-producing carbapenemase-producing Enterobacterales (CPE) present significant therapeutic challenges due to resistance to most β-lactam agents, including carbapenems. Aztreonam combined with avibactam (ATM/AVI) provides a promising treatment strategy, but standardized antimicrobial susceptibility testing (AST) methods remain limited. This study evaluated the performance of the MTS™ ATM/AVI gradient strip (Liofilchem) with the CLSI-recommended ceftazidime-avibactam plus aztreonam (CZA/ATM) broth disk elution (BDE) method in 36 CPE and 9 Stenotrophomonas maltophilia clinical isolates. Categorical agreement between these methods was 97.2 % for CPE and 88.9 % for S. maltophilia. Whole-genome sequencing was used for discrepancy analysis. Based on accuracy, reproducibility, and ease of use, the ATM/AVI gradient strip was selected as the preferred method for clinical laboratory testing.
21 August 2025 in Clinical Chemistry
Background: Next-generation sequencing for hepatitis B virus (HBV) and cytomegalovirus (CMV) antiviral drug resistance (AVDR) testing improves the sensitivity of variant detection, but availability of bioinformatics and analytical pipelines are key barriers to implementation. Methods: Plasma was extracted on MagNA Pure 24 (Roche Diagnostics) and next-generation sequencing performed on GridION (Oxford Nanopore Technologies) with R.10.4.1 flowcells. An in-house bioinformatics pipeline was developed using Nextflow and deployed on Microsoft Azure to process FASTQ files and automate reporting of HBV genotype and AVDR, as well as CMV AVDR (UL97/54). Results: A total of 71 samples for HBV genotyping and AVDR testing and 56 samples for CMV AVDR testing were analyzed and compared to reference pipelines (DeepChek® HBV and CMV). All HBV genotypes and resistant mutations were concordant. For CMV, 74 mutations were identified in the UL97/54 region by both pipelines. However, our in-house developed method identified an additional UL97 drug resistant mutation (del598-603) in one sample. Conclusions: A custom bioinformatics pipeline was developed for HBV and CMV genotyping and AVDR sequencing, which could be adapted to other targets to enable our clinical laboratory to expand clinical testing using next-generation sequencing.
29 July 2025 in Diagnostic Microbiology and Infectious Disease
Timely identification of extended-spectrum beta-lactamase (ESBL)-producing bacteria supports early antimicrobial optimization, especially for patients with invasive infections. NG-Test® CTX-M MULTI (CTX-M LFA) is a rapid immunochromatographic assay for detection of Cefotaximase-Munich (CTX-M)-type ESBL. We evaluated its performance against existing molecular platforms. A sampling of archived Gram-negative bacteria (including Enterobacterales and non-fermenters) was included in the study. All isolates underwent testing for CTX-M ESBL by CTX-M LFA. CTX-M LFA results were compared to results from molecular methods, laboratory-developed (LD)-PCR (2013-2019) or BCID2 (2022-2023). Discordances were resolved with a combination of ESBL phenotypic testing and an alternative PCR platform, or whole-genome sequencing. Seventy-eight isolates were included in the study, all of which underwent CTX-M LFA and molecular testing (n = 47 by LD-PCR, n = 31 by BCID2). Post-discordance analysis showed positive percent agreement of 89.7 % (95 %CI 71.5-97.2 %), negative percent agreement 100 % (95 %CI 90.9-100 %) and overall categorical agreement 96.2 %, κ=0.92 (95 %CI 88.4-99.0 %). One E. coli was negative by CTX-M LFA but positive for blaCTX-M by BCID2. Whole-genome sequencing identified a non-functional blaCTX-M-27 gene with adenine insertion at position 70 in codon 24, causing a frameshift mutation resulting in a premature stop codon (codon 58). CTX-M LFA improved performance in comparison with molecular methods by accurately identifying an isolate with a prematurely truncated protein as a true-negative for CTX-M. This highlights potential limitations of molecular-based resistance detection. CTX-M LFA was simple to perform and yielded results within 15 minutes.